Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence
Introduction and hypothesis To evaluate the effects of oral anticholinergic (OAC) drugs on tear secretion in women with overactive bladder over a 3-month follow-up period. Methods In this prospective study, 108 women with a diagnosis of overactive bladder were evaluated. All patients were examined o...
Gespeichert in:
Veröffentlicht in: | International Urogynecology Journal 2016-06, Vol.27 (6), p.919-922 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction and hypothesis
To evaluate the effects of oral anticholinergic (OAC) drugs on tear secretion in women with overactive bladder over a 3-month follow-up period.
Methods
In this prospective study, 108 women with a diagnosis of overactive bladder were evaluated. All patients were examined ophthalmologically at baseline (day 0), and after 1 month (day 30) and 3 months (day 90) of OAC treatment. Tear film break-up time (BUT) and Schirmer 1 test results were recorded. The subjective complaints of the patients including dry mouth, and burning, dryness and foreign body sensation in the eyes, were also recorded. The chi-squared test or the paired sample
t
test as appropriate, was used for statistical analysis.
Results
The mean age of the patients was 51.8 ± 9.2 years (30 – 69 years). The most frequent subjective complaints were dry mouth and dry eyes and both complaints were significant on both day 30 and day 90. Both tear film BUT and Schirmer 1 test results were significantly lower on day 30 and day 90. Dry eye measurement values worsened with prolongation of OAC treatment (
p
= 0.037 and
p
= 0.012 for BUT, and
p
= 0.046 and
p
= 0.035 for Schirmer 1 test, on day 30 and day 90, respectively).
Conclusions
OAC treatment in women with overactive bladder significantly and progressively affects tear secretion. |
---|---|
ISSN: | 0937-3462 1433-3023 |
DOI: | 10.1007/s00192-015-2911-6 |